|
Daehan New Pharm expects to expand exports to Ethiopia
2008.07.29
|
|---|
|
Daehan New Pharm Co., Ltd. (CEO Bae Kun-Woo) successfully completed the GMP inspection conducted by the Ethiopian Ministry of Health in June and received final approval of compliance on July 16. As a result, the company expects to export more than USD 1–2 million worth of finished pharmaceuticals and veterinary medicines annually to Ethiopia in the coming years.
Daehan New Pharm has consistently exported veterinary medicines to Ethiopia since 2002, starting with USD 320,000 and maintaining annual exports of USD 400,000–500,000. With this GMP approval, the company has now established a foothold to supply its core human pharmaceutical products, including cephalosporin antibiotics and anticancer drugs, to the Ethiopian market.
Although Ethiopia is a developing country, it manages its pharmaceutical regulations in accordance with international standards, including WHO GMP criteria. Therefore, the outcome of this inspection carries significant meaning. Moreover, due to the declining presence of competing supplier nations such as India, Pakistan, and China in the Ethiopian pharmaceutical import market, the company’s export prospects are looking even brighter.
Daehan New Pharm currently exports cephalosporin-based pharmaceuticals such as ceftriaxone, ceftazidime, and cefpodoxime to more than 20 countries worldwide, including Vietnam, Pakistan, and Cuba. The company is also actively expanding exports of major products such as streptokinase (a thrombolytic agent), and anticancer drugs including carboplatin, dacarbazine, and dactinomycin.
Meanwhile, in November 2007, Daehan New Pharm received the USD 5 Million Export Tower Award at the 44th Trade Day celebration. The company continues to strengthen its overseas partnerships and develop strategic export products with strong market potential, aiming to achieve USD 10 million in annual exports within the next few years. |


Home